Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor  VIII Replacement in Severe Hemophilia A

ConclusionsPS-adjusted analyses were consistent with prior intra-individual comparisons. Compared with participants receiving prophylactic FVIII, the participants receiving valoctocogene roxaparvovec experienced lower ABR, and a higher proportion had zero bleeds.Trail RegistrationClinicalTrials.gov identifier, NCT03370913.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research